Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation.
Yang X, Liu Q, Li Y, Ding Y, Zhao Y, Tang Q, Wu T, Chen L, Pu S, Cheng S, Zhang J, Zhang Z, Huang Y, Li R, Zhao Y, Zou M, Shi X, Jiang W, Wang R, He J.
Yang X, et al. Among authors: wang r.
Br J Pharmacol. 2021 Apr;178(8):1756-1771. doi: 10.1111/bph.15381. Epub 2021 Mar 1.
Br J Pharmacol. 2021.
PMID: 33480065
Free article.